An Open Label Dose Ascending, Single Dose Study to Investigate the Pharmacokinetics of SB-656933 in Subjects With Cystic Fibrosis.
Latest Information Update: 03 Jul 2023
At a glance
- Drugs Elubrixin (Primary)
- Indications Cystic fibrosis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 16 Jun 2014 New trial record
- 19 Feb 2010
- 10 Apr 2008